In NSCLC, targeting the STAT3/VEGF axis can significantly reduce tumor‐associated VEGF, angiogenesis, and vascular permeability in lung cancer cells, indicating the therapeutic significance of inhibiting STAT3 (Mohrherr et al. 2020; Kang et al. 2019). Here, VEGFA is linked to non-small cell lung carcinoma.